health smarts. ALS "Revolution"

July 2012
PN;Jul2012, Vol. 66 Issue 7, p30
Trade Publication
The article focuses on drugs dexpramipexole and ceftriaxone which are in Phase III clinical trials with large numbers of patients receiving the drug or a placebo over the period of six months or more to be used for amyotrophic lateral sclerosis (ALS) therapies.


Related Articles

  • Augie's Quest Carries Fight Against ALS to UCI Medical Center. REED, VITA // Orange County Business Journal;2/18/2013, Vol. 36 Issue 7, p1 

    The article reports that the ALS Therapy Development Institute, led by Augie Nieto, an amyotrophic lateral scelrosis (ALS), has received approval from the U.S. Food and Drug Administration for its clinical trial of the TDI-132 drug for the treatment of the said condition.

  • Another blow for ALS. Sinha, Gunjan // Nature Biotechnology;Mar2013, Vol. 31 Issue 3, p185 

    The article reports on the failure of the experimental drug dexpramipexole to treat amyotrophic lateral sclerosis (ALS) or motor neuron disease, wherein, Biogen Idec Inc. in Weston, Massachusetts discontinued clinical trials after no benefits had been shown in phase 3 trial of 943 patients.

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.

  • Understanding Lou Gehrig's disease.  // Patient Care;2/28/1997, Vol. 31 Issue 4, p16 

    Reports on the nationwide program to develop guidelines for the treatment of amyotyhrophic lateral sclerosis (ALS) in the United States. Prevalence of ALS in the country; Contact information for physicians and patients interested to participate in the program.

  • A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. Bensimon, G.; Lacomblez, L.; Meininger, V. // New England Journal of Medicine;3/3/94, Vol. 330 Issue 9, p585 

    Background: Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis. Methods: To evaluate the efficacy and safety of the...

  • ALS drug slows progression. Rodgers, Katie // Drug Topics;11/20/95, Vol. 139 Issue 22, p52 

    Reports on the findings of a phase III clinical trial presented at the SiSixt International Symposium on amyotrophic lateral sclerosis.motor neuron disease.

  • Nerve preserver. Munson, Marty; Higbee, Beth // Prevention;Nov95, Vol. 47 Issue 11, p58 

    Reports on the results of a pilot study on a drug used for staving off the crippling effects of Lou Gehrig's disease or amyotrophic lateral sclerosis published in the March 3, 1994 issue of the `New England Journal of Medicine'. Possibility of a prolonged survival; Availability of other...

  • Update on amyotrophic lateral sclerosis. R.M.D. // Cortlandt Forum;11/25/96, Vol. 9 Issue 11, p121 

    Responds to an inquiry regarding recommended treatment for amyotrophic lateral sclerosis.

  • ALS guidelines.  // Drug Topics;12/9/96, Vol. 140 Issue 23, p32 

    Reports on the creation of the Amyotrophic Lateral Sclerosis Clinical Assessment, Research and Education (CARE) Program to study practice patterns and treatment guidelines. Funding from Rhone-Poulenc Rorer; Goal of improving treatment and quality of life of patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics